
Cerebrolysin
Potential Benefits
- Approved in multiple countries for acute ischemic stroke and traumatic brain injury
- Clinical trials suggest potential benefits for vascular dementia and Alzheimer's disease
- Research indicates neurotrophic effects similar to BDNF, NGF, and CNTF
- May support neuroplasticity and synaptic remodeling based on clinical data
- Meta-analyses of stroke trials suggest improvements in neurological outcomes
Recommended Starting Dose
5-10 mL intravenously per day for cognitive applications (clinical doses range from 10-30 mL for acute stroke)
Based on published research protocols. Not a prescription.
Dosing Protocol
In clinical settings, Cerebrolysin is administered IV at 10-30 mL daily for stroke (typically diluted in saline over 15-60 minutes) for 10-21 days. For cognitive support, lower doses of 5-10 mL IV or IM daily for 10-20 day cycles, repeated every 1-3 months, are used. Must be administered by healthcare professionals.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
In stroke trials, neurological improvements were assessed at 30 and 90 days. For cognitive applications, benefits may be measured over weeks to months of cyclical treatment.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Must be administered intravenously or intramuscularly (not available orally)
- Headache
- Dizziness
- Injection site reactions
- Agitation in some patients
- Rare allergic reactions
- Fever in some cases
- Derived from animal tissue, which may concern some individuals
More in Cognitive

Selank
Selank
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the naturally occurring immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for stability. It is approved in Russia as an anxiolytic and nootropic nasal spray.

Semax
Semax
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added Pro-Gly-Pro C-terminal tripeptide for metabolic stability. Developed in Russia, it is approved there for conditions including stroke recovery, cognitive disorders, and peptic ulcers. It is administered intranasally.

Dihexa
Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. Developed at Washington State University by Dr. Joseph Harding, it was found to be up to 10 million times more potent than BDNF at promoting hepatocyte growth factor (HGF) signaling. Research has focused on its potential to drive synaptogenesis and cognitive enhancement.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.